Form 4: BrightSpring Health Services Grants Equity Awards to PharMerica President

BrightSpring Health Services has granted restricted stock units and stock options to Scott A. Greenwell, President of its PharMerica division, as part of his compensation.

Summary

• Scott A. Greenwell, President of PharMerica at BrightSpring Health Services, Inc. (BTSG), was granted 16,839 restricted stock units (RSUs) and 35,920 stock options.
• The RSUs represent a contingent right to receive one share of common stock upon settlement and are scheduled to vest in three equal annual installments commencing June 20, 2026.
• The stock options have an exercise price of $22.27 per share and will also vest in three equal annual installments beginning June 20, 2026, with an expiration date of June 20, 2035.
• Both the RSU and option grants were reported with a transaction date of June 20, 2025, and were acquired at a price of $0, indicating they are compensation grants.
• Following these transactions, Mr. Greenwell directly beneficially owns 16,839 shares of common stock (from RSUs) and 35,920 stock options.

Sentiment

Score: 7

Explanation: The filing indicates a routine executive compensation grant, which is generally positive as it aligns management's interests with shareholders, but it does not represent a significant new development or financial performance indicator.

Positives

• The grant of restricted stock units and stock options aligns the interests of President Scott A. Greenwell with those of shareholders, incentivizing long-term performance.
• Equity compensation is a common practice to retain key executives and motivate them to contribute to the company's growth.

Negatives

• The equity awards are subject to future vesting schedules, meaning the full benefit is not immediately realized and is contingent on continued employment and performance.
• The value of the stock options and RSUs is dependent on the future market price of BrightSpring Health Services' common stock, introducing market risk.

Future Outlook

The future outlook for Scott A. Greenwell's ownership includes the vesting of 16,839 restricted stock units and 35,920 stock options in three equal annual installments beginning June 20, 2026, contingent on his continued employment and the company's performance. The stock options will expire on June 20, 2035.

Industry Context

This is a routine executive compensation grant, a common practice across various industries, including healthcare services, to attract, retain, and incentivize key management personnel by aligning their financial interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units and stock options with multi-year vesting schedules is a standard component of executive compensation packages in the healthcare services industry, comparable to practices at companies like Encompass Health Corporation (EHC) or LHC Group (LHCG) before its acquisition, which also utilize equity incentives to align executive performance with shareholder returns.
• The vesting schedule of three equal annual installments is a common structure designed to encourage long-term commitment and performance, similar to equity incentive plans observed at other publicly traded healthcare providers.

Related Party Transactions

• The grant of 16,839 restricted stock units and 35,920 stock options to Scott A. Greenwell, President of PharMerica, constitutes a related party transaction as it involves compensation from the company to an executive officer.

Stakeholder Impact

• Shareholders: The equity grants are intended to align the interests of a key executive with shareholders, potentially leading to improved long-term company performance and shareholder value.
• Employees: The compensation structure for executives can set a precedent or reflect the company's overall approach to incentivizing its workforce.

Next Steps

• The restricted stock units will begin vesting in three equal annual installments starting June 20, 2026.
• The stock options will begin vesting in three equal annual installments starting June 20, 2026.

Key Dates

Recommendation

This Form 4 reports a routine equity compensation grant to an executive. While it aligns management's interests with shareholders, it does not provide new fundamental information about the company's financial performance, strategic direction, or market position that would warrant a change in investment recommendation. It's a standard operational disclosure.

Keywords

BrightSpring Health Services, BTSG, Scott A. Greenwell, PharMerica, Form 4, SEC filing, insider transaction, restricted stock units, RSUs, stock options, executive compensation, equity grant, beneficial ownership